# Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist

> **NCT01914757** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2508 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Benralizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01914757
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 2508 (ACTUAL)
- **Last updated:** 2017-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01914757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01914757, "Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01914757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*